Neurohormonal consequences of diuretics in different cardiovascular syndromes

Détails

ID Serval
serval:BIB_25A92BFAAB1B
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Neurohormonal consequences of diuretics in different cardiovascular syndromes
Périodique
European Heart Journal
Auteur⸱e⸱s
Burnier  M., Brunner  H. R.
ISSN
0195-668X (Print)
Statut éditorial
Publié
Date de publication
12/1992
Volume
13 Suppl G
Pages
28-33
Notes
Journal Article
Research Support, Non-U.S. Gov't
Review --- Old month value: Dec
Résumé
Diuretics have long been used to lower blood pressure in hypertensive patients or to control body fluid and electrolyte homeostasis in diseases such as congestive heart failure, chronic renal failure or cirrhosis. The initial response to diuretics is a negative sodium and fluid balance. The diuretic-induced loss of salt and water activates several hormonal systems such as vasopressin, the renin-angiotensin-aldosterone system or the sympathetic nervous system which tend to compensate for the changes in sodium and water balance. This neurohormonal response may have important clinical implications. Thus, the activation of the renin-angiotensin-aldosterone cascade appears to be partially responsible for the flat dose-blood pressure response curve of thiazides in hypertensive patients. It may also be responsible for the difference between responders and non-responders to diuretic therapy and for the development of side-effects such as hypokalaemia, metabolic alkalosis or hyponatraemia. There are several ways to prevent the undesirable consequences of the neurohormonal responses to diuretics. The first is to use low doses of these agents. It is also possible to combine them with agents that block the activity of the renin-angiotensin-aldosterone system such as ACE inhibitors or in combination with drugs that reduce aldosterone secretion such as calcium antagonists. The development of drugs able to enhance urinary sodium excretion and to reduce simultaneously the activity of the renin-angiotensin-aldosterone system may offer a new interesting alternative. This might perhaps be achieved in the future with the administration of neutral endopeptidase inhibitors which interfere with the enzymatic degradation of atrial natriuretic peptide.
Mots-clé
Animals Cardiovascular Diseases/*drug therapy/physiopathology Diuretics/adverse effects/*therapeutic use Humans Hypertension/drug therapy/physiopathology Neurotransmitter Agents/*physiology Renin-Angiotensin System/drug effects Water-Electrolyte Balance/drug effects
Pubmed
Web of science
Création de la notice
25/01/2008 13:56
Dernière modification de la notice
20/08/2019 14:04
Données d'usage